Inovio Pharmaceuticals Inc. (NASDAQ:INO) finished Wednesday with an addition of $0.07 to close at $6.99, an upside of 1.01 percent. An average of 2,264,280 shares of common stock have been traded in the last five days. There was a gain of $0.58 in the past week. The last 20 days have seen an average of 3,370,045 shares traded, while the 50-day average volume stands at 4,575,176.
INO stock has decreased by -7.17% in the last month. The company shares reached their 1-month lowest point of $6.34 on 10/04/21. With the stock rallying to its 52-week high on 02/02/21, shares of the company touched a low of $5.81 and a high of $19.00 in 52 weeks. In spite of this, the price is down -63.21% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
66 days have passed since Inovio Pharmaceuticals Inc. (INO) last reported insider trading activity. Humeau Laurent, who is Chief Scientific Officer, most recently acquired $10,317 shares at $9.15 per share on Aug 09. In this transaction, the insider spent $94,401. Chief Operating Officer, Shea Jacqueline Elizabeth, disposed of 38,535 shares at a price of $10.01 on Jun 09. The insider now owns more than $385,735 worth of shares. Prior to that, Chief Scientific Officer Humeau Laurent went on to Sale 10,318 shares at $9.07 each on Jun 09. An amount of $93,584 was transacted.
Inovio Pharmaceuticals Inc. (INO) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 0.61. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 228.98, the price-to-book (PB) ratio at 2.88.
The company’s most recent quarterly dividend payment was $0.0690 a share, without any change from last year.
The quick ratio of Inovio Pharmaceuticals Inc. for the three months ended June 29 was 10.50, and the current ratio was 10.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.03 and a total debt to equity ratio of 0.03 for the quarter ending June 29. Inovio Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -1698.16%. Its gross profit as reported stood at $131.49 million compared to revenue of $7.41 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Inovio Pharmaceuticals Inc.’s return on assets was -25.50%, compared to -56.7% over the last five years. In the past year, the return on investment has been -24.90%, and the 5-year average is -75.1%. Meanwhile, the return on equity (ROE) for the past 12 months has been -30.20% and the 5-year average holds at -107.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Inovio Pharmaceuticals Inc. had $384.75 million in cash. The analyst consensus anticipated Inovio Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.39, a -56.00% surprise. For the quarter, EBITDA amounted to -$82.37 million. Shareholders own equity worth $210.36 million.
From a technical analysis perspective, let’s take a brief look at Inovio Pharmaceuticals Inc. (INO) price momentum. RSI 9-day as of the close on 13 October was 47.05%, suggesting the stock is Neutral, with historical volatility in this time frame at 56.67%.
As of today, INO’s price is $6.78 +9.05% or $0.58 from its 5-day moving average. INO is currently trading -7.66% lower than its 20-day SMA and -0.99% lower than its 100-day SMA. However, the stock’s current price level is -18.82% below the SMA50 and -27.19% below the SMA200.
The stochastic %K and %D were 33.14% and 25.39%, respectively, and the average true range (ATR) was 0.32. With the 14-day stochastic at 38.23% and the average true range at 0.36, the RSI (14) stands at 43.26%. The stock has reached 0.25 on the 9-day MACD Oscillator while the 14-day reading was at -0.04.
BofA Securities downgraded Inovio Pharmaceuticals Inc. (NASDAQ: INO) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Inovio Pharmaceuticals Inc. (INO) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell INO, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is INO’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $35.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for Inovio Pharmaceuticals Inc. (INO) stock is $13.22.